Alendronate sodium/vitamin D3 for senile patients with osteoporosis after total hip arthroplasty

doi:10.3969/j.issn.2095-4344.2017.15.002

Abstract：BACKGROUND: Adverse events following total hip arthroplasty are commonly seen in elderly osteoporotic patients,especially prosthetic loosening caused by reduced bone density surrounding the prosthesis, which even needs reversion.OBJECTIVE: To investigate the effectiveness and safety of alendronate sodium/vitamin D3 for total hip arthroplasty in elderly patients with osteoporosis.METHODS: Seventy-four patients with osteoporosis were randomized to experimental and control groups (n=37 per group), and both received total hip arthroplasty, followed by the calcium supplementary treatment at 1-2 weeks.Meanwhile, the patients in the experimental group were orally given alendronate sodium/vitamin D3 (70 mg), once weekly. The course was 6 months in both two groups.RESULTS AND CONCLUSION: In the experimental group, the bone mineral density of the lumbar vertebrae and contralateral hip were significantly increased at 3, 6 and 12 months postoperatively compared with baseline, and also significantly higher than those in the control group (P < 0.05). (2) The incidence of aseptic loosening and prosthesis adjacent fracture did not differ significantly between two groups (P > 0.05). (3) The serum levels of creatinine,phosphorus and calcium all kept in normal values at baseline and 3, 6 and 12 months postoperatively in both two groups,and showed no significant differences before and after treatment between two groups (P > 0.05). (4) These findings indicate that alendronate sodium/vitamin D3 can effectively increase the bone mineral density of elderly osteoporotic patients after total hip arthroplasty free of significant adverse effects, and exposes no effect on renal function and calcium-phosphorus metabolism.